Your Health, Our CoMPaSS
Your Health, Our CoMPaSS
The project aims to improve the quality of life of patients suffering from Hereditary Neuromuscular Diseases (HNMDs) and their caregivers, by adopting a new multidimensional approach based on Artificial Intelligence (AI) for better and faster personalised diagnoses and treatments.
HNMDs often strike early in life, causing severe disabilities and significantly reducing life expectancy. These conditions hinder daily functioning, leading to social isolation and the need for constant care. Many patients require long-term institutionalisation, putting strain on both families and healthcare systems.
What does Compass do?
In CoMPaSS-NMD, Artificial Intelligence guides the physicians towards a more accurate diagnosis of HNMDs.
COMPASS-NMD will analyse a large amount of diverse data sources, collected from the clinical centres partners of the project, among which genetic and clinical information, creating one of the most advanced diagnostic computational tools.
Artificial intelligence will give the chance to identify connections between data that are not recognisable with standard methods, extending the diagnostic proficiencies of the physicians.
Impact
The main expected outcomes of the project are:
- An AI-based method leading to a faster and more accurate diagnosis of HNMDs able to promote effective actions by European national health systems, ameliorating the quality of life of patients and caregivers and reducing needless expenses.
- The CoMPaSS-NMD Neuromuscular Genome Atlas: a repository of genetic, imaging, and histopathological data of HNMD patients from six clinical centres in five countries, which will incentivise the development of strategies that integrate health data to support patients, healthcare professionals and citizens.
The project aims to improve the quality of life of patients suffering from Hereditary Neuromuscular Diseases (HNMDs) and their caregivers, by adopting a new multidimensional approach based on Artificial Intelligence (AI) for better and faster personalised diagnoses and treatments.
HNMDs often strike early in life, causing severe disabilities and significantly reducing life expectancy. These conditions hinder daily functioning, leading to social isolation and the need for constant care. Many patients require long-term institutionalisation, putting strain on both families and healthcare systems.
What does Compass do?
In CoMPaSS-NMD, Artificial Intelligence guides the physicians towards a more accurate diagnosis of HNMDs.
COMPASS-NMD will analyse a large amount of diverse data sources, collected from the clinical centres partners of the project, among which genetic and clinical information, creating one of the most advanced diagnostic computational tools.
Artificial intelligence will give the chance to identify connections between data that are not recognisable with standard methods, extending the diagnostic proficiencies of the physicians.
Impact
The main expected outcomes of the project are:
- An AI-based method leading to a faster and more accurate diagnosis of HNMDs able to promote effective actions by European national health systems, ameliorating the quality of life of patients and caregivers and reducing needless expenses.
- The CoMPaSS-NMD Neuromuscular Genome Atlas: a repository of genetic, imaging, and histopathological data of HNMD patients from six clinical centres in five countries, which will incentivise the development of strategies that integrate health data to support patients, healthcare professionals and citizens.